Successful selective arterial embolizations for bone metastases in renal cell carcinoma integrated with systemic therapies: A case report
| Autor: | Maristella Saponara, Margherita Nannini, Giancarlo Facchini, Maria Abbondanza Pantaleo, Lidia Gatto, Giulio Rossi, V. Di Scioscio, Guido Biasco |
|---|---|
| Přispěvatelé: | Gatto L, Facchini G, Saponara M, Nannini M, Rossi G, Di Scioscio V, Biasco G, Pantaleo MA. |
| Rok vydání: | 2017 |
| Předmět: |
lcsh:Medical physics. Medical radiology. Nuclear medicine
Sorafenib medicine.medical_specialty Bone disease lcsh:R895-920 medicine.medical_treatment Arterial embolization Locoregional therapy 030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine Renal cell carcinoma Interventional Radiology Medicine Radiology Nuclear Medicine and imaging business.industry Sunitinib Bone metastases Arterial Embolization Bone metastasis medicine.disease Surgery Radiation therapy Bone metastase 030220 oncology & carcinogenesis Radiology business Progressive disease Integration strategy medicine.drug |
| Zdroj: | Radiology Case Reports Radiology Case Reports, Vol 12, Iss 4, Pp 775-779 (2017) |
| ISSN: | 1930-0433 |
| DOI: | 10.1016/j.radcr.2017.07.008 |
| Popis: | Herein is described the case of a 64-year-old patient affected by metastatic clear-cell carcinoma, with exclusive bone disease, subjected after the initial cytoreductive nephrectomy to 3 successive lines of medical treatment (sunitinib, everolimus, and sorafenib) and multiple locoregional treatments (spinal surgery, radiation therapy, and selective arterial embolization), resulting in a surprisingly long survival of over 75 months. In the era of target therapy, integration strategies, including additional locoregional treatment to medical therapy, are essential to optimize the clinical benefit, to maximize treatment duration overcoming focal progressive disease, and to improve the quality of life. In this context, we would highlight that selective transcatheter embolization of bone metastases from renal cell carcinoma should be considered as an effective and safe option in the palliative setting for patients with bone metastasis, especially for pain relief. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|